Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research
The DOI matches its Crossref record; 204 of the 205 references it cites were found in a registry or an index.
Abstract
Psychiatric disorders represent a large economic burden in modern societies. However, pharmacological treatments are still far from optimal. Drugs used in the treatment of major depressive disorder (MDD) and anxiety disorders (selective serotonin [5-HT] reuptake inhibitors [SSRIs] and serotonin-noradrenaline reuptake inhibitors [SNRIs]) are pharmacological refinements of first-generation tricyclic drugs, discovered by serendipity, and show low efficacy and slowness of onset. Moreover, antipsychotic drugs are partly effective in positive symptoms of schizophrenia, yet they poorly treat negative symptoms and cognitive deficits. The present article reviews the neurobiological basis of 5-HT1A receptor (5-HT1A-R) function and the role of pre- and postsynaptic 5-HT1A-Rs in the treatment of MDD, anxiety and psychotic disorders. The activation of postsynaptic 5-HT1A-Rs in corticolimbic areas appears beneficial for the therapeutic action of antidepressant drugs. However, presynaptic 5-HT1A-Rs play a detrimental role in MDD, since individuals with high density or function of presynaptic 5-HT1A-Rs are more susceptible to mood disorders and suicide, and respond poorly to antidepressant drugs. Moreover, the indirect activation of presynaptic 5-HT1A-Rs by SSRIs/SNRIs reduces 5-HT neuron activity and terminal 5-HT release, thus opposing the elevation of extracellular 5-HT produced by blockade of the serotonin transporter (SERT) in the forebrain. Chronic antidepressant treatment desensitizes presynaptic 5-HT1A-Rs, thus reducing the effectiveness of the 5-HT1A autoreceptor-mediated negative feedback. The prevention of this process by the non-selective partial agonist pindolol accelerates clinical antidepressant effects. Two new antidepressant drugs, vilazodone (marketed in the USA) and vortioxetine (in development) incorporate partial 5-HT1A-R agonist properties with SERT blockade. Several studies with transgenic mice have also established the respective role of pre- and postsynaptic 5-HT1A-Rs in MDD and anxiety. In agreement with pharmacological studies, presynaptic and postsynaptic 5-HT1A-R activation appears necessary for anxiolytic and antidepressant effects, respectively, yet, neurodevelopmental roles for 5-HT1A-Rs are also involved. Likewise, the use of small interference RNA has enabled the showing of robust antidepressant-like effects in mice after selective knock-down of 5-HT1A autoreceptors. Postsynaptic 5-HT1A-Rs in the prefrontal cortex (PFC) also appear important for the superior clinical effects of clozapine and other second-generation (atypical) antipsychotic drugs in the treatment of schizophrenia and related psychotic disorders. Despite showing a moderate in vitro affinity for 5-HT1A-Rs in binding assays, clozapine displays functional agonist properties at this receptor type in vivo. The stimulation of 5-HT1A-Rs in the PFC leads to the distal activation of the mesocortical pathway and to an increased dopamine release in PFC, an effect likely involved in the clinical actions of clozapine in negative symptoms and cognitive deficits in schizophrenia. The anxiolytic/antidepressant properties of 5-HT1A-R agonists in preclinical tests raised expectations enormously. However, these agents have achieved little clinical success, possibly due to their partial agonist character at postsynaptic 5-HT1A-Rs, together with full agonist properties at presynaptic 5-HT1A autoreceptors, as well as their gastrointestinal side effects. The partial 5-HT1A-R agonists buspirone, gepirone, and tandospirone are marketed as anxiolytic drugs, and buspirone is also used as an augmentation strategy in MDD. The development of new 5-HT1A-R agonists with selectivity for postsynaptic 5-HT1A-Rs may open new perspectives in the field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Presynaptic 5-HT(1A) and 5HT(1B) auto-receptors play a major detrimental role in antidepressant treatments [45].”
Citations
Cites
Items 201–204 of 204
An Open Study of Buspirone Augmentation of Neuroleptics in Patients With Schizophrenia
Sirota, P., Epstein, B., Benatov, R., Sousnostzky, M., & Kindler, S. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00015 · Cited by 20
Unresolved Questions About Treatment-Resistant Anxiety Disorders
Stein, D. J., & Seedat, S. (2004) · CNS Spectrums · doi:10.1017/s1092852900022355 · Cited by 15
Rauly‐Lestienne, I., Lestienne, F., Ailhaud, M., Binesse, J., Newman‐Tancredi, A., & Cussac, D. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.08.002 · Cited by 14 · cited 1×
“Postsynaptic 5-HT1A-Rs are coupled to various members of the Gi/o protein family [46, 47], thus stimulating inhibitory intracellular signaling mechanisms [48, 49].”
Lexicon of Psychiatry, Neurology, and the Neuroscience, 2nd. ed
Rao, N. R. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0214c · Cited by 6 · cited 1×
“pressant efficacy in pilot studies [102, 103].”
Research works printed but not linked: 1
- Greenberg BD, Li Q, Lucas FR, et al. Association between the serotonin transporter promoter polymorphism and personality traits in a primarily female population sample. Am J Med Genet. 2000;96:202–16. · DOI · Paper page
Cited by
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 695
“Mechanisms underlying the anxiolytic effects of 5-HT1AR activation are complex, varying between both brain region, and pre- versus postsynaptic locus, and are not fully established [56].”
BackgroundSerotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
“…may inform on the function of brain serotonin, one may think of enhancing 5-HT2AR signalling as analogous to increasing the temperature (or excitability) of the brain; indeed, the excitatory effect of 5-HT2AR signalling has long been recognised (Aghajanian and Marek, 1999; Celada et al., 2013b).”
BackgroundResultInfluentialPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“As noted above, buspirone has been FDA-approved for the treatment of anxiety, which led to the consideration of other azapirones (100).”
BackgroundThe Roles of Serotonin in Neuropsychiatric Disorders
Pourhamzeh, M., Moravej, F. G., Arabi, M., Shahriari, E., Mehrabi, S., Ward, R., Ahadi, R., & Joghataei, M. T. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01064-9 · Cited by 366
Structure and function of serotonin G protein-coupled receptors
McCorvy, J. D., & Roth, B. L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.009 · Cited by 372
“The 5HT1A receptor has been implicated in anxiety, and as mentioned, novel anti-depressants and antipsychotics have begun to incorporate partial 5-HT1A agonist activity to enhance their efficacy in such diseases (Celada et al., 2013).”
Influential
Metadata
- Authors
- Celada, P., Bortolozzi, A., & Artigas, F.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- Corresponding author
- Artigas, Francesc
- Venue
- CNS Drugs
- Published
- 2013-06-12
- Volume
- 27
- Issue
- 9
- Pages
- 703-716
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2054695075
- Cited by
- 323
- References
- 205
- Citations by year
- 2026: 13 · 2025: 25 · 2024: 22 · 2023: 26 · 2022: 15 · 2021: 28 · 2020: 22 · 2019: 23 · 2018: 26 · 2017: 31 · 2016: 26 · 2015: 34 · 2014: 25 · 2013: 7
- FWCI
- 15.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Funders
- Les Laboratories Pierre Fabre
- Generalitat de Catalunya
- Centro de Investigación Biomédica en Red de Salud Mental
- Instituto de Salud Carlos III
- European Regional Development Fund
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- 5-HT1A receptor, postsynaptic 5-HT1A receptors, major depressive disorder, anxiety disorders, schizophrenia, antidepressant mechanism, serotonin transporter, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, pindolol, vilazodone, vortioxetine, partial agonists, negative feedback, brain development, siRNA
- MeSH terms
- Animals, Mental Disorders, Humans, Receptors, Serotonin, 5-HT1, Serotonin 5-HT1 Receptor Agonists, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.